[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394. doi: 10.3322/caac.21492
[2] 王洛伟, 李兆申. 食管癌早诊早治现状及展望[J]. 中国实用内科杂志, 2019, 39(7): 605.
[3] LYU S, LU J, CHEN W, et al. High expression of eIF4A2 is associated with a poor prognosis in esophageal squamous cell carcinoma[J]. Oncol Lett, 2020, 20(5): 177.
[4] MOON SH, SUH YG. The role of modern radiotherapy technology in the treatment of esophageal cancer[J]. Korean J Thorac Cardiovasc Surg, 2020, 53(4): 184. doi: 10.5090/kjtcs.2020.53.4.184
[5] BOUSTANI J, RIVIN DEL CAMPO E, et al. Quality assurance of dose-escalated radiation therapy in a randomized trial for locally advanced oesophageal cancer[J]. Int J Radiat Oncol Biol Phys, 2019, 105(2): 329. doi: 10.1016/j.ijrobp.2019.06.2542
[6] LIU S, REN SN, DING WX, et al. Concurrent liposomal paclitaxel and cisplatin chemotherapy improved outcomes for locally advanced esophageal squamous cell carcinoma treated with intensity-modulated radiotherapy[J]. Ann Transl Med, 2019, 7(14): 331. doi: 10.21037/atm.2019.06.45
[7] 曹晓岚, 胡旭东. 化疗方案对食管癌放疗的增效作用研究进展[J]. 肿瘤, 2017, 37(11): 1238.
[8] CHEN NB, QIU B, ZHANG J, et al. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in definitive chemoradiotherapy for cervical esophageal squamous cell carcinoma: comparison of survival outcomes and toxicities[J]. Cancer Res Treat, 2020, 52(1): 31. doi: 10.4143/crt.2018.624
[9] 白文文, 宋玉芝, 乔永志, 等. 食管鳞癌SIB-IMRT疗效及预后因素分析[J]. 中华放射肿瘤学杂志, 2018, 27(6): 570.
[10] 方文涛. 通过食管癌TNM新分期(第八版)解读2017年NCCN食管鳞癌诊疗指南[J]. 中华胃肠外科杂志, 2017, 20(10): 1122.
[11] MIN BH, YANG JW, MIN YW, et al. Nomogram for prediction of lymph node metastasis in patients with superficial esophageal squamous cell carcinoma[J]. J Gastroenterol Hepatol, 2020, 35(6): 1009. doi: 10.1111/jgh.14915
[12] LI W, LIU J, ZHAO H. Identification of a nomogram based on long non-coding RNA to improve prognosis prediction of esophageal squamous cell carcinoma[J]. Aging(Albany NY), 2020, 12(2): 1512.
[13] 张耀文, 郑安平, 郑志勇, 等. 食管鳞癌术后局部复发三维适形调强放疗预后因素分析[J]. 中华肿瘤防治杂志, 2015, 22(12): 969.
[14] 赵晶晶, 庞青松, 王平. 食管癌根治性放疗剂量研究进展[J]. 中华放射肿瘤学杂志, 2020, 29(7): 589.
[15] ISHIDA Y, SAKANAKA K, FUJⅡ K, et al. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma without hypopharyngeal invasion: dose distribution and clinical outcome[J]. J Radiat Res, 2019, 60(4): 517. doi: 10.1093/jrr/rrz019
[16] REN X, WANG L, HAN C, et al. Retrospective analysis of safety profile of high-dose concurrent chemoradiotherapy for patients with oesophageal squamous cell carcinoma[J]. Radiother Oncol, 2018, 129(2): 293. doi: 10.1016/j.radonc.2018.09.006
[17] 程志远, 孙枫原, 孟茜茜, 等. 食管癌单纯性骨转移183例预后因素分析及预测模型构建[J]. 中国实用内科杂志, 2019, 39(7): 624.
[18] BETANCOURT-CUELLAR SL, BENVENISTE MFK, PALACIO DP, et al. Esophageal cancer: tumor-node-metastasis staging[J]. Radiol Clin North Am, 2021, 59(2): 219. doi: 10.1016/j.rcl.2020.11.008
[19] 吴盛喜, 罗何三, 张晓平, 等. 胸中段食管癌放化疗后远期生存Nomogram预测模型建立[J]. 中华肿瘤防治杂志, 2018, 25(6): 417.
[20] WU L, OU J, CHEN TW, et al. Tumour volume of resectable oesophageal squamous cell carcinoma measured with MRI correlates well with T category and lymphatic metastasis[J]. Eur Radiol, 2018, 28(11): 4757. doi: 10.1007/s00330-018-5477-0
[21] FANG FM, TSAI WL, CHIU HC, et al. Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2004, 58(5): 1394. doi: 10.1016/j.ijrobp.2003.09.100
[22] DE B, RHOME R, DOUCETTE J, et al. Dose escalation of definitive radiation is not associated with improved survival for cervical esophageal cancer: a National Cancer Data Base(NCDB) analysis[J]. Dis Esophagus, 2017, 30(4): 1.
[23] TANG X, ZHOU X, LI Y, et al. A novel nomogram and risk classification system predicting the cancer-specific survival of patients with initially diagnosed metastatic esophageal cancer: a seer-based Study[J]. Ann Surg Oncol, 2019, 26(2): 321. doi: 10.1245/s10434-018-6929-0